Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.
TLDR
In this paper, a review of the development and use of JAK inhibitors in COVID-19, from artificial intelligence to current clinical evidence, including real world experience, and critically appraise emerging safety issues, namely infections, thrombosis, and liver injury.Citations
More filters
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.
Masoumeh Farahani,Zahra Niknam,Leila Mohammadi Amirabad,Nasrin Amiri-Dashatan,Mehdi Koushki,Mohadeseh Nemati,Fahima Danesh Pouya,Mostafa Rezaei-Tavirani,Yousef Rasmi,Lobat Tayebi +9 more
TL;DR: In this article, a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in-vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
TL;DR: In this paper , a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot,Christiane S. Eberhardt,Tobias Boettler,Luca S. Belli,Marina Berenguer,Maria Buti,Rajiv Jalan,Mario U. Mondelli,Richard Moreau,Daniel Shouval,Thomas Berg,Markus Cornberg +11 more
TL;DR: The European Association for the Study of the Liver as mentioned in this paper provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation.
Journal ArticleDOI
JAK inhibitors and COVID-19
TL;DR: Whether a class effect of JAKi may be emerging in COVID-19 treatment, although at the moment the convincing data are for baricitinib only is discussed, because the precise timing of treatment will be very important in future trials.
Journal ArticleDOI
JAK-STAT Pathway: A Novel Target to Tackle Viral Infections
TL;DR: In this article, the authors review the diversity of strategies that viruses have evolved to interfere with JAK-STAT signaling, stressing the relevance of this pathway as a putative antiviral target.
References
More filters
Journal ArticleDOI
Basic Mechanisms of JAK Inhibition
TL;DR: It is important to understand both the role of cytokines in regulating immune function and the JAK-STAT pathways in order to fully appreciate the true value of JAK inhibition, especially in relation to its role in diseases such as RA.
Journal ArticleDOI
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Dave Singh,Maxim Bogus,Valentyn Moskalenko,RW Lord,Edmund J. Moran,Glenn Crater,David L. Bourdet,Nathan D. Pfeifer,Jacky Woo,Elad Kaufman,David A. Lombardi,Emily Y. Weng,Tuan Nguyen,Ashley Woodcock,Brett Haumann,Rajeev Saggar +15 more
TL;DR: The inhaled lung selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebohttps://bit.ly/35Xs1Rf
Journal ArticleDOI
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
TL;DR: The authors retrospectively investigated adverse events (AEs) by data-mining a self-reporting database to better understand toxicities, especially since it has been used during the coronavirus disease 2019 pandemic.
Journal ArticleDOI
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Antonella Cingolani,A. M. Tummolo,G. Montemurro,Elisa Gremese,L. Larosa,M. C. Cipriani,G. Pasciuto,R. Liperoti,Rita Murri,T. Pirronti,Roberto Cauda,Massimo Fantoni +11 more
TL;DR: A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.
Journal ArticleDOI
JAK inhibitors in 2019, synthetic review in 10 points.
TL;DR: A systematic review of JAK inhibitors, from their mechanism of physiological action up to the estimation of their current risk benefit balance, and their possible future applications is proposed.